---
layout: default
title: Ramosetron
parent: Model Prediction Only (L5)
nav_order: 716
evidence_level: L5
indication_count: 2
---

# Ramosetron
{: .fs-9 }

Evidence Level: **L5** | Predicted Indications: **2** 
{: .fs-6 .fw-300 }

---

## Table of Contents
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## Pharmacist Assessment Report

</div>

# Ramosetron: From IBS-D/CINV to Insomnia

## One-Sentence Summary

Ramosetron is a selective 5-HT3 receptor antagonist known pharmacologically for use in irritable bowel syndrome with diarrhea (IBS-D) and chemotherapy-induced nausea and vomiting (approved in Japan/Korea; no India regulatory data on file).
The TxGNN model predicts it may be effective for **Insomnia**,
but currently **no clinical trials** and **no publications** support this direction — the prediction rests on the knowledge graph score alone.

---

## Quick Overview

| Item | Content |
|------|------|
| Original Indication | IBS-D / Chemotherapy-Induced Nausea and Vomiting (based on known 5-HT3 antagonist classification; no India license data available) |
| Predicted New Indication | Insomnia |
| TxGNN Prediction Score | 99.73% |
| Evidence Level | L5 |
| India Market Status | Not Marketed |
| Number of Registrations | 0 |
| Recommended Decision | Hold |

---

## Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available. Based on known information, ramosetron is a selective 5-HT3 receptor antagonist, a class primarily used for IBS-D and chemotherapy-induced nausea/vomiting through blockade of serotonin signaling in the gut and central chemoreceptor trigger zone.

The proposed link to insomnia relies on the theoretical involvement of 5-HT3 receptors in central serotonergic transmission, which is broadly connected to sleep-wake regulation. However, this connection is speculative — there is no pharmacological, preclinical, or clinical data specifically tying ramosetron's mechanism to sleep-wake cycle modulation. The evidence pack itself flags this as a "theoretical inference only," which is why the evidence level is capped at L5 (model prediction only).

A second candidate, migraine disorder (score 99.06%), was also flagged, drawing on the loose precedent of other 5-HT3 antagonists (e.g., ondansetron) being used off-label for migraine-associated nausea — but again this is symptomatic, not mechanism-targeted, and lacks any ramosetron-specific evidence.

---

## Clinical Trial Evidence

Currently no related clinical trials registered

---

## Literature Evidence

Currently no related literature available

---

## India Market Information

No registration records are currently available for ramosetron in India (market status: Not Marketed, 0 licenses on file).

---

## Safety Considerations

Please refer to the package insert for safety information.

*Note: TFDA-equivalent label warnings/contraindications are flagged as a **Blocking** data gap (DG001) — this must be resolved before any S1 safety pre-assessment can proceed.*

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
The prediction is supported only by a TxGNN knowledge-graph score with no corroborating clinical trials, literature, or established mechanistic pathway (evidence level L5). Combined with the absence of India market presence and missing label/safety data, this candidate does not meet the threshold to advance.

**To proceed, the following is needed:**
- Confirmed mechanism of action (MOA) data from DrugBank or primary literature
- Local label warnings/contraindications (DG001 — currently blocking)
- Preclinical or mechanistic evidence linking 5-HT3 antagonism to sleep-wake regulation
- At minimum, early-phase clinical or observational data before re-scoring above L5
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

